MEDICATIONS USED IN THE TREATMENT OF ADHD AND THEIR EFFECTS ON THE CARDIOVASCULAR SYSTEM
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6425Keywords:
Attention-Deficit/Hyperactivity Disorder (ADHD); ADHD Medications; Cardiovascular Effects; Arrhythmias; Blood Pressure; Cardiovascular MonitoringAbstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder frequently requiring long-term pharmacological treatment. The medications used in ADHD management, particularly stimulant agents and non-stimulant therapies, may influence cardiovascular function through effects on sympathetic activity, heart rate, and vascular tone. This review summarizes the available evidence regarding the potential association between ADHD medications and cardiovascular outcomes, with particular emphasis on arrhythmias and changes in arterial blood pressure. We analyze findings from previously published studies evaluating the effects of pharmacological treatment on blood pressure, heart rate, and the occurrence or risk of cardiac rhythm disturbances in children, adolescents, and adults with ADHD. Current evidence suggests that ADHD medications may be associated with modest changes in blood pressure and heart rate, although the clinical significance of these effects varies among individuals and treatment modalities. The potential risk of arrhythmias remains an important consideration, particularly in patients with pre-existing cardiovascular disease or other risk factors. The review highlights the importance of individualized risk assessment, baseline cardiovascular evaluation, and appropriate monitoring during treatment. Further research is needed to clarify long-term cardiovascular outcomes and identify patients who may be particularly susceptible to adverse cardiovascular effects.
References
Gondek, T. M., Todzia-Kornaś, A., & Szczegielniak, A. (2023). Stanowisko grupy badawczej Female ADHD Research Group i Sekcji Kształcenia Specjalizacyjnego PTP dotyczące kontrowersyjnych doniesień medialnych na temat ADHD u osób dorosłych. Psychiatria Spersonalizowana / Personalized Psychiatry, 2(4), 125–127. https://doi.org/10.5114/psychs.2023.135314
Galileo Medical. (n.d.). Statystyki ADHD w Polsce – najnowsze dane – 2025. https://galileomedical.pl/zdrowie-psychiczne/statystyki-adhd-w-polsce/
Ayano, G., Demelash, S., Gizachew, Y., Tsegay, L., & Alati, R. (2023). The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. Journal of Affective Disorders, 339, 860–866. https://doi.org/10.1016/j.jad.2023.07.071
Gondek, T. M., Stramecki, F., Cieśla, M., Ziegart-Sadowska, K., Foryciarz, K., Główczyński, P., et al. (2025). Assessment and management of adults with ADHD. Guidelines of the Specialty Training Section of the Polish Psychiatric Association and a coalition of organizations for people with ADHD – update, 2025. Psychiatria Spersonalizowana / Personalized Psychiatry, 4(1), 80–115. https://doi.org/10.5114/psychs.2025.154273
Cichoń, L., Jelonek, I., & Janas-Kozik, M. (2017). ADHD – wskazówki praktyczne: Farmakoterapia i prowadzenie dokumentacji. Psychiatria i Psychologia Kliniczna, 17(4), 270–273. https://doi.org/10.15557/pipk.2017.0031
Shin, J., Roughead, E. E., Park, B., & Pratt, N. L. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): Nationwide self controlled case series study. BMJ, 353, i2550. https://doi.org/10.1136/bmj.i2550
Brown, K. A., Samuel, S., & Patel, D. R. (2018). Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: A review for practitioners. Translational Pediatrics, 7(1), 36–47. https://doi.org/10.21037/tp.2017.08.02
Lewars, J. T., & Wiarda, K. P. (2023). Amphetamine-dextroamphetamine-induced cardiomyopathy, an emerging cause of heart failure in young patient populations: A case study involving the study drug. Cureus, 15(6), e40942. https://doi.org/10.7759/cureus.40942
Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187. https://doi.org/10.1001/jamapsychiatry.2023.4294
Jabbar Abdl Sattar Hamoudi, H., Abdelkhalek, A., Mwangi, B., & Abdelkhalek, O. (2025). Abstract 4367866: Prescription stimulants can increase risk of arrhythmias: Systematic review and meta-analysis. Circulation, 152(Suppl. 3). https://doi.org/10.1161/circ.152.suppl_3.4367866
Torres-Acosta, N., O’Keefe, J. H., O’Keefe, C. L., & Lavie, C. J. (2020). Cardiovascular effects of ADHD therapies. Journal of the American College of Cardiology, 76(7), 858–866. https://doi.org/10.1016/j.jacc.2020.05.081
Liang, E. F., Lim, S. Z., Tam, W. W., Ho, C. S., Zhang, M. W., McIntyre, R. S., & Ho, R. C. (2018). The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): Systematic review, meta-analysis, and meta-regression. International Journal of Environmental Research and Public Health, 15(8), 1789. https://doi.org/10.3390/ijerph15081789
Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE Consortium. (2017). Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs, 31(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
National Institute for Health and Care Excellence. (2019). Attention deficit hyperactivity disorder: Diagnosis and management.
Farhat, L. C., Lannes, A., Del Giovane, C., Parlatini, V., Garcia-Argibay, M., Ostinelli, E. G., Tomlinson, A., Chang, Z., Larsson, H., Fava, C., Montastruc, F., Cipriani, A., Revet, A., & Cortese, S. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 12(5), 355–365. https://doi.org/10.1016/S2215-0366(25)00062-8
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., West, S., Kelsey, D., Wernicke, J., Trapp, N. J., & Harder, D. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. The American Journal of Psychiatry, 159(11), 1896–1901. https://doi.org/10.1176/appi.ajp.159.11.1896
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., Fireman, B. H., Fish, F. A., Kirshner, H. S., O'Duffy, A., Connell, F. A., & Ray, W. A. (2011). ADHD drugs and serious cardiovascular events in children and young adults. The New England Journal of Medicine, 365(20), 1896–1904. https://doi.org/10.1056/NEJMoa1110212
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., Andrade, S. E., Pawloski, P. A., Raebel, M. A., Smith, D. H., Achacoso, N., Uratsu, C., Go, A. S., Sidney, S., Nguyen-Huynh, M. N., . . . Selby, J. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA, 306(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maria Nowakowska, Kornelia Tyczka, Maria Sierant, Kamila Zmysłowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
